Gastrointestinal 1
==NILAI PRETEST Pre-postest Gastrointestinal 1
318 Disorders of Absorption Henry J. Binder Disorders of absorption constitute a broad spectrum of conditions with multiple etiologies and varied clinical manifestations. Almost all of these clinical problems are associated with diminished intestinal absorp tion of one or more dietary nutrients and are often referred to as the malabsorption syndrome. This term is not ideal as it represents a patho physiologic state, does not provide an etiologic explanation for the underlying problem, and should not be considered an adequate final diagnosis. The only clinical conditions in which absorption is increased are hemochromatosis and Wilson’s disease, in which absorption of iron and copper, respectively, is elevated. Most malabsorption syndromes are associated with steatorrhea, an increase in stool fat excretion to >7% of dietary fat intake. Some malab sorption disorders are not associated with steatorrhea: primary lactase deficiency, a congenital absence of the small-intestinal brush border disaccharidase enzyme lactase, is associated with lactose “malabsorp tion,” and pernicious anemia is associated with a marked decrease in intestinal absorption of cobalamin (vitamin B12 ) due to an absence of gastric parietal-cell intrinsic factor, which is required for cobalamin PART 10 Disorders of the Gastrointestinal System absorption. Disorders of absorption must be included in the differential diagno sis of diarrhea (Chap. 42). First, diarrhea is frequently associated with and/or is a consequence of the diminished absorption of one or more dietary nutrients. The diarrhea may be secondary either to the intesti nal process that is responsible for the steatorrhea or to steatorrhea per se. Thus, celiac disease (see below) is associated with both extensive morphologic changes in the small-intestinal mucosa and reduced absorption of several dietary nutrients; in contrast, the diarrhea of steatorrhea is the result of the effect of nonabsorbed dietary fatty acids on intestinal (usually colonic) ion transport. For example, oleic and ric inoleic acids (a bacterially hydroxylated fatty acid that is also the active ingredient in castor oil, a widely used laxative) induce active colonic Cl ion secretion, most likely secondary to increasing intracellular Ca. In addition, diarrhea per se may result in mild steatorrhea (<11 g of fat excretion while on a 100-g fat diet). Second, most patients will indicate that they have diarrhea, not that they have fat malabsorption. Third, many intestinal disorders that have diarrhea as a prominent symptom (e.g., ulcerative colitis, traveler’s diarrhea secondary to an enterotoxin produced by Escherichia coli) do not necessarily have diminished absorption of any dietary nutrient. Diarrhea as a symptom (i.e., when the term is used by patients to describe their bowel movement pattern) may reflect a decrease in stool consistency, an increase in stool volume, an increase in number of bowel movements, or any combination of these three changes. In contrast, diarrhea as a sign is a quantitative increase in stool water or weight of >200–225 mL or g per 24 h when a Western-type diet is consumed. Individuals consuming a diet with higher-fiber content may normally have a stool weight of up to 400 g/24 h. Thus, the clinician must clarify what an individual patient means by diarrhea. Some 10% of patients referred to gastroenterologists for further evaluation of unexplained diarrhea do not have an increase in stool water when this variable is determined quantitatively. Such patients may have small, frequent, somewhat loose bowel movements with stool urgency that is indicative of proctitis, but do not have an increase in stool weight or volume. In addition, an occasional patient will describe their fecal incontinence as diarrhea due to social embarrassment. It is also critical to establish whether a patient’s diarrhea is second ary to diminished absorption of one or more dietary nutrients rather than being due to small- and/or large-intestinal fluid and electrolyte secretion. The former has often been termed osmotic diarrhea, while the latter has been referred to as secretory diarrhea. Unfortunately, both secretory and osmotic elements can be present simultaneously in the same disorder; thus, this distinction is not always precise. Nonetheless, two studies—determination of stool electrolytes and observation of the effect of a fast on stool output—can help make this distinction. The demonstration of the effect of prolonged (>24 h) fasting on stool output can suggest that a dietary nutrient is responsible for the individ ual’s diarrhea. Secretory diarrhea associated with enterotoxin-induced traveler’s diarrhea would not be affected by prolonged fasting, as enterotoxin-induced stimulation of intestinal fluid and electrolyte secretion is not altered by eating. In contrast, diarrhea secondary to lactose malabsorption in primary lactase deficiency would undoubt edly cease during a prolonged fast. Thus, a substantial decrease in stool output by a fasting patient during quantitative stool collection lasting at least 24 h is presumptive evidence that the diarrhea is related to malabsorption of one or more dietary nutrients. The persistence of stool output during fasting indicates that the diarrhea is likely secretory and that its cause is not a dietary nutrient. Either a luminal (e.g., E. coli enterotoxin) or a circulating (e.g., vasoactive intestinal peptide) secretagogue could be responsible for unaltered persistence of a patient’s diarrhea during a prolonged fast. The observed effects of fasting can be compared and correlated with stool electrolyte and osmolality determinations. Measurement of stool electrolytes and osmolality requires compari son of Na+ and K+ concentrations in liquid stool with the osmolality of the stool in order to determine the presence or absence of a so-called stool osmotic gap. The following formula is used: 2 = (stool [Na+] + stool [K+]) 9 stool osmolality The cation concentrations are doubled to estimate stool anion concentrations. The presence of a significant osmotic gap suggests the presence in stool water of a substance (or substances) other than Na/K/anions, which is presumably responsible for the patient’s diar rhea. Originally, stool osmolality was measured, but it is almost invari ably greater than the required 290–300 mosmol/kg H2 O, reflecting bacterial degradation of nonabsorbed carbohydrate either immediately before defecation or in the stool jar while specimen awaits chemical analysis, even when the stool is refrigerated. As a result, the stool osmolality should be assumed to be 300 mosmol/kg H2 O. A low stool osmolality (<290 mosmol/kg H2 O) reflects the addition of either dilute urine or water, indicating either collection of urine and stool together or so-called factitious diarrhea, a form of Münchausen’s syndrome. When the calculated difference in the formula above is >50, an osmotic gap exists; its presence suggests that the diarrhea is due to a nonabsorbed dietary nutrient—for example a fatty acid and/or a carbohydrate. When this difference is <25, it is presumed that a dietary nutrient is not responsible for the diarrhea. Since elements of both osmotic diarrhea (i.e., due to malabsorption of a dietary nutrient) and secretory diarrhea may be present, this distinction at times is less clear-cut at the bedside than when used as a teaching example. Ideally, the presence of an osmotic gap will be associated with a marked decrease in stool output during a prolonged fast, while an osmotic gap will likely be absent in an individual whose stool output is not reduced substantially during a period of fasting. NUTRIENT DIGESTION AND ABSORPTION The lengths of the small intestine and the colon are ~300 and ~80 cm, respectively. However, the effective functional surface area is ~600 fold greater than that of a hollow tube as a result of folds, villi (in the small intestine), and microvilli. The functional surface area of the small intestine is somewhat greater than that of a doubles tennis court. In addition to nutrient digestion and absorption, the intestinal epithelia have several other functions: 1. Barrier and immune defense. The intestine is exposed to a large num ber of potential antigens and enteric and invasive microorganisms, and it is extremely effective at preventing the entry of almost all of these agents. The intestinal mucosa also synthesizes and secretes secretory IgA. 2. Fluid and electrolyte absorption and secretion. The intestine absorbs ~7–8 L of fluid daily, a volume comprising dietary fluid intake (1–2 L/d) and salivary, gastric, pancreatic, biliary, and intestinal NORMAL 2245 fluid (6–7 L/d). Several stimuli, especially bacteria and bacterial enterotoxins, induce fluid and electrolyte secretion that may lead to diarrhea (Chap. 128). 3. Synthesis and secretion of several proteins. The intestinal mucosa is a major site for the production of proteins, including apolipoproteins. 4. Production of several bioactive amines and peptides. The intestine is one of the largest endocrine organs in the body and produces several amines (e.g., 5-hydroxytryptophan) and peptides that serve as para crine and hormonal mediators of intestinal function. The small and large intestines are distinct anatomically (villi are present in the small intestine but are absent in the colon) and func tionally (nutrient digestion and absorption take place in the small intestine but not in the colon). No precise anatomic characteristics sep arate duodenum, jejunum, and ileum, although certain nutrients are absorbed exclusively in specific areas of the small intestine. However, villous cells in the small intestine (surface epithelial cells in the colon) and crypt cells have distinct anatomic and functional characteristics. Intestinal epithelial cells are continuously renewed; new proliferating epithelial cells at the base of the crypt migrate over 48–72 h to the tip of the villus (or surface of the colon), where they exist as well-developed epithelial cells with digestive and absorptive function. This high rate of cell turnover explains the relatively rapid resolution of diarrhea and other digestive-tract side effects during chemotherapy as new cells not exposed to these toxic agents are produced. Equally important is the paradigm of separation of villous/surface cell and crypt cell functions. Digestive hydrolytic enzymes are present primarily in the brush border of villous epithelial cells. Absorptive and secretory functions are also separate: villous/surface cells are primarily, but not exclusively, the site for absorptive function, while secretory function is located in crypts of both the small and large intestines. Nutrients, minerals, and vitamins are absorbed by one or more active-transport mechanisms. These mechanisms are energy dependent and are mediated by membrane transport proteins. These processes will result in the net movement of a substance against or in the absence of an electrochemical concentration gradient. Intestinal absorption of amino acids and monosaccharides (e.g., glucose) is also a specialized form of active transport—secondary active transport. The movement of actively transported nutrients against a concentration gradient is Na+ dependent and is due to a Na+ gradient across the apical membrane. The Na+ gradient is maintained by Na+,K+-adenosine triphosphatase (ATPase), the so-called Na+ pump located on the basolateral mem brane, which extrudes Na+ and maintains low intracellular [Na] as well as the Na+ gradient across the apical membrane. As a result, active glucose absorption and glucose-stimulated Na+ absorption require both the apical membrane transport protein SGLT1 and the basolateral Na+,K+-ATPase. In addition to requiring Na+ for its absorption, glucose stimulates Na+ and fluid absorption; this effect is the physiologic basis of oral rehydration therapy for the treatment of diarrhea (Chap. 42). The mechanisms of intestinal fluid and electrolyte absorption and secretion are discussed in Chap. 42. Although the intestinal epithelial cells are crucial mediators of absorption and of ion and water flow, the several cell types in the lamina propria (e.g., mast cells, macrophages, myofibroblasts) and the enteric nervous system interact with the epithelium to regulate mucosal cell function. Intestinal function results from the integrated responses and interactions of intestinal epithelial cells and intestinal muscle. ■ENTEROHEPATIC CIRCULATION OF BILE ACIDS Bile acids are not present in the diet but are synthesized in the liver by a series of enzymatic steps that also represent cholesterol catabolism. Indeed, interruption of the enterohepatic circulation of bile acids can reduce serum cholesterol levels by 10% before a new steady state is established. Bile acids are either primary or secondary. Primary bile acids are synthesized in the liver from cholesterol, and secondary bile acids are synthesized from primary bile acids in the intestine by colonic bacterial enzymes. The two primary bile acids in humans are cholic acid and chenodeoxycholic acid; the two most abundant secondary bile acids are deoxycholic acid and lithocholic acid. The liver synthesizes Cholesterol Bile acids 0.5 g synthesized per day [Bile acids] >4 mM Bile acid pool size 4.0 g Jejunum Ileum Na 0.5 g Bile acids excreted per day COLON FIGURE 318-1 Schematic representation of the enterohepatic circulation of bile acids. Bile-acid synthesis is cholesterol catabolism and occurs in the liver. Bile acids are secreted in bile and are stored in the gallbladder between meals and at night. Food in the duodenum induces the release of cholecystokinin, a potent stimulus for gallbladder contraction resulting in bile-acid entry into the duodenum. Bile acids are primarily absorbed via an Na-dependent transport process that is located only in the ileum. A relatively small quantity of bile acids (~500 mg) is not absorbed in a 24-h period and is lost in stool. Fecal bile-acid losses are matched by bile-acid synthesis. The bile-acid pool (the total amount of bile acids in the body) is ~4 g and is circulated twice during each meal or six to eight times in a 24-h period. ~500 mg of bile acids daily; the bile acids are conjugated to either taurine or glycine (to form tauroconjugated and glycoconjugated bile acids, respectively) and are secreted into the duodenum in bile. The primary functions of bile acids are to (1) promote bile flow, (2) solubi lize cholesterol and phospholipid in the gallbladder by mixed micelle formation, and (3) enhance dietary lipid digestion and absorption by forming mixed micelles in the proximal small intestine. Bile acids are primarily absorbed by an active, Na+-dependent pro cess that takes place exclusively in the ileum; to a lesser extent, they are absorbed by non-carrier-mediated transport processes in the jejunum, ileum, and colon. Conjugated bile acids that enter the colon are decon jugated by colonic bacterial enzymes. The unconjugated bile acids are rapidly absorbed by nonionic diffusion. Colonic bacterial enzymes also dehydroxylate bile acids to secondary bile acids. Bile acids absorbed from the intestine return to the liver via the portal vein and are then re-secreted (Fig. 318-1). Bile-acid synthesis is largely autoregulated by 7α-hydroxylase, the initial enzyme in choles terol degradation. A decrease in the quantity of bile acids returning to the liver from the intestine is associated with an increase in bile-acid synthesis/cholesterol catabolism (mediated by fibroblast growth factor [FGF19]), which helps keep the bile-acid pool size relatively constant. However, the capacity to increase bile-acid synthesis is limited to ~2- to 2.5-fold (see below). The bile-acid pool size is ~4 g. The pool is circu lated via the enterohepatic circulation about twice during each meal, or six to eight times during a 24-h period. A relatively small quantity of bile acids is not absorbed and is excreted in stool daily; this fecal loss is matched by hepatic bile-acid synthesis. Defects in any of the steps in enterohepatic circulation of bile acids can result in a decrease in the duodenal concentration of conjugated bile acids and consequently in the development of steatorrhea. Thus, steatorrhea can be caused by abnormalities in bile-acid synthesis and excretion, their physical state in the intestinal lumen, and reabsorption (Table 318-1). CHAPTER 318 Disorders of Absorption Synthesis Decreased bile-acid synthesis and steatorrhea have been demonstrated in chronic liver disease, but steatorrhea often is not a major component of illness in these patients. Secretion Although bile-acid secretion may be reduced or absent in biliary obstruction, steatorrhea is rarely a significant medical 2246 TABLE 318-1 Defects in Enterohepatic Circulation of Bile Acids PROCESS Synthesis Biliary secretion Maintenance of conjugated bile acids Reabsorption PATHOPHYSIOLOGIC DEFECT Decreased hepatic function Altered canalicular function Bacterial overgrowth Abnormal ileal function DISEASE EXAMPLE Cirrhosis Primary biliary cirrhosis Jejunal diverticulosis Crohn’s disease problem in these patients. In contrast, primary biliary cirrhosis rep resents a defect in canalicular excretion of organic anions, including bile acids, and not infrequently is associated with steatorrhea and its consequences (e.g., chronic bone disease). Thus, the osteopenia/ osteomalacia and other chronic bone abnormalities often present in patients with primary biliary cirrhosis and other cholestatic syndromes are secondary to steatorrhea that then leads to calcium and vitamin D malabsorption as well as to the effects of cholestasis (e.g., bile acids and inflammatory cytokines). Maintenance of Conjugated Bile Acids In bacterial over PART 10 Disorders of the Gastrointestinal System growth syndromes associated with diarrhea, steatorrhea, and macro cytic anemia, a colonic type of bacterial flora is increased in the small intestine. Steatorrhea is primarily a result of the decrease in conjugated bile acids secondary to their deconjugation by colonic-type bacteria. Two complementary explanations account for the resulting impairment of micelle formation: (1) Unconjugated bile acids are rapidly absorbed in the jejunum by nonionic diffusion, and the result is a reduced con centration of duodenal bile acids; and (2) the critical micellar concentra tion (CMC) of unconjugated bile acids is higher than that of conjugated bile acids; therefore, unconjugated bile acids are less effective than conjugated bile acids in micelle formation. Reabsorption Ileal dysfunction caused by either Crohn’s disease or surgical resection results in a decrease in bile-acid reabsorption in the ileum and an increase in the delivery of bile acids to the large intestine. The resulting clinical consequences—diarrhea with or without steatorrhea— are determined by the degree of ileal dysfunction and the response of the enterohepatic circulation to bile-acid losses (Table 318-2). Patients with limited ileal disease or resection often have diarrhea but not steatorrhea. The diarrhea, a result of stimulation of active Cl secretion by bile acids in the colon, has been called bile-acid diarrhea or choleretic enteropathy and responds promptly to cholestyramine, an anion-binding resin. Steatorrhea does not develop because hepatic synthesis of bile acids increases to compensate for the rate of fecal bile-acid losses, resulting in maintenance of both the bile-acid pool size and the intraduodenal concentrations of bile acids. In contrast, patients with greater degrees of ileal disease and/or resection often have diarrhea and steatorrhea that do not respond to cholestyramine. In this situation, ileal disease is also associated with increased volumes of bile acids entering the colon; however, hepatic synthesis can no longer increase sufficiently to maintain the bile-acid pool size. As a consequence, the intraduode nal concentration of bile acids is reduced to less than the CMC, and TABLE 318-3 Comparison of Different Types of Fatty Acids LONG-CHAIN Carbon chain length Present in diet Origin Primary site of absorption Requires pancreatic lipolysis Requires micelle formation Present in stool >12 In large amounts In diet as triglycerides Small intestine TABLE 318-2 Comparison of Bile Acid and Fatty Acid Diarrhea BILE-ACID DIARRHEA Extent of ileal disease Limited Ileal bile-acid absorption Reduced Fecal bile-acid excretion Fecal bile-acid loss compensated by hepatic synthesis Bile-acid pool size Increased Yes Normal Intraduodenal (bile acid) Normal Steatorrhea Response to cholestyramine None or mild Yes Response to low-fat diet No FATTY ACID DIARRHEA Extensive Reduced Increased No Reduced Reduced >20 g No Yes the result is impaired micelle formation and steatorrhea. This second situation is often called fatty acid diarrhea. Cholestyramine may not be effective (and may even exacerbate the diarrhea by further depleting the intraduodenal bile-acid concentration); however, a low-fat diet to reduce fatty acid entry into the colon can be effective. Two clinical features—the length of the ileal section removed and the degree of steatorrhea—can predict whether an individual patient will respond to cholestyramine. Unfortunately, these predictors are imperfect, and a therapeutic trial of cholestyramine is often necessary to establish whether an individual patient will benefit from cholestyramine. Table 318-2 contrasts the characteristics of bile-acid diarrhea (small ileal dysfunction) and fatty acid diarrhea (large ileal dysfunction). Bile-acid diarrhea can also occur in the absence of ileal inflammation and/or resection and is characterized by an abnormal 75SeHCAT reten tion study and reduced ileal release of FGF19, a negative regulator of bile-acid synthesis, with a consequent increase in bile-acid synthesis and secretion that exceeds ileal bile-acid absorption. The diarrhea in these patients also responds to cholestyramine. ■LIPIDS Steatorrhea is caused by one or more defects in the digestion and absorp tion of dietary fat. The average intake of dietary fat in the United States is ~120–150 g/d, and fat absorption is linear to dietary fat intake. The total load of fat presented to the small intestine is considerably greater, as substantial amounts of lipid are secreted in bile each day (see “Entero hepatic Circulation of Bile Acids,” above). Three types of fatty acids compose fats: long-chain fatty acids (LCFAs), medium-chain fatty acids (MCFAs), and short-chain fatty acids (SCFAs) (Table 318-3). Dietary fat is exclusively composed of long-chain triglycerides (LCTs)—that is, glycerol that is bound via ester linkages to three LCFAs. While the majority of dietary LCFAs have carbon chain lengths of 16 or 18, all fatty acids of carbon chain length >12 are metabolized in the same manner; saturated and unsaturated fatty acids are handled identically. Assimilation of dietary lipid requires three integrated processes: (1) an intraluminal, or digestive, phase; (2) a mucosal, or absorptive, phase; and (3) a delivery, or postabsorptive, phase. An abnormality at any site involved in these processes can cause steatorrhea (Table 318-4). Therefore, it is essential that any patient with steatorrhea be evaluated MEDIUM-CHAIN 8–12 In small amounts SHORT-CHAIN <8 No Only in small amounts in diet as triglycerides Small intestine Yes Yes No No No Bacterial degradation in colon of nonabsorbed carbohydrate to fatty acids Colon No No Minimal Substantial 2247 TABLE 318-4 Defects in Lipid Digestion and Absorption in Steatorrhea PHASE, PROCESS Digestive Lipolysis formation Micelle formation Absorptive Mucosal uptake and re-esterification Postabsorptive Chylomicron formation Delivery from intestine PATHOPHYSIOLOGIC DEFECT Decreased lipase secretion Decreased intraduodenal bile acids Mucosal dysfunction Absent β-lipoproteins Abnormal lymphatics DISEASE EXAMPLE Chronic pancreatitis See Table 318-1 Celiac disease Abetalipoproteinemia Intestinal lymphangiectasia to identify the specific physiologic defect in overall lipid digestion/ absorption, as therapy will be determined by the specific etiology. The digestive phase has two components: lipolysis and micelle for mation. Although dietary lipid is in the form of LCTs, the intestinal mucosa does not absorb triglycerides; they must first be hydrolyzed (Fig. 318-2). The initial step in lipid digestion is the formation of emul sions of finely dispersed lipid, which is accomplished by mastication and gastric contractions. Lipolysis, the hydrolysis of triglycerides to free fatty acids, monoglycerides, and glycerol by lipase, is initiated in the stomach by lingual and gastric lipases that have a pH optimum of 4.5–6.0. About 20–30% of total lipolysis occurs in the stomach. Lipolysis is completed in the duodenum and jejunum by pancreatic lipase, which is inactivated by a pH <7.0. Pancreatic lipolysis is greatly enhanced by the presence of a second pancreatic enzyme, colipase, which facilitates the movement of lipase to the triglyceride. Impaired lipolysis can lead to steatorrhea and can occur in the pres ence of pancreatic insufficiency due to chronic pancreatitis in adults or cystic fibrosis in children and adolescents. Normal lipolysis can be maintained by ~5% of maximal pancreatic lipase secretion; thus, steatorrhea is a late manifestation of these disorders. A reduction in intraduodenal pH can also result in altered lipolysis, as pancreatic lipase is inactivated at pH <7. Thus, ~15% of patients who have gastri noma (Chap. 317), with substantial increases in gastric acid secretion from ectopic production of gastrin (usually from an islet cell adenoma), have diarrhea, and some have steatorrhea believed to be secondary to acid inactivation of pancreatic lipase. Similarly, patients who have chronic pancreatitis (with reduced lipase secretion) often have a decrease in pancreatic bicarbonate secretion, which will also result in a Pancreas Liver Jejunal Mucosa lowering of intraduodenal pH and inactivation of endogenous pancre atic lipase or of therapeutically administered lipase. Overlying the microvillus membrane of the small intestine is the so-called unstirred water layer, a relatively stagnant aqueous phase that must be traversed by the products of lipolysis that are primarily water insoluble. Water-soluble mixed micelles provide a mechanism by which the water-insoluble products of lipolysis can reach the luminal plasma membrane of villous epithelial cells—the site for lipid absorption. Mixed micelles are molecular aggregates composed of fatty acids, monoglycerides, phospholipids, cholesterol, and conjugated bile acids. These mixed micelles are formed when the concentration of conjugated bile acids is greater than its CMC, which differs among the several bile acids present in the small-intestinal lumen. Conjugated bile acids, synthesized in the liver and excreted into the duodenum in bile, are regulated by the enterohepatic circulation (see above). Steat orrhea can result from impaired movement of fatty acids across the unstirred aqueous fluid layer in two situations: (1) an increase in the relative thickness of the unstirred water layer that occurs in bacterial overgrowth syndromes (see below) secondary to functional stasis (e.g., scleroderma); and (2) a decrease in the duodenal concentration of conjugated bile acids below the CMC, resulting in impaired micelle formation. Thus, steatorrhea can be caused by one or more defects in the enterohepatic circulation of bile acids. Uptake and re-esterification constitute the absorptive phase of lipid digestion/absorption. Although passive diffusion has been thought to be responsible, a carrier-mediated process may mediate fatty acid and monoglyceride uptake. Regardless of the uptake process, fatty acids and monoglycerides are re-esterified by a series of enzymatic steps in the endoplasmic reticulum to form triglycerides, in which lipid exits from the intestinal epithelial cell. Impaired lipid absorption as a result of mucosal inflammation (e.g., celiac disease) and/or intestinal resec tion can also lead to steatorrhea. The re-esterified triglycerides require the formation of chylomicrons to permit their exit from the small-intestinal epithelial cell and their delivery to the liver via the lymphatics. Chylomicrons are composed of β-lipoprotein and contain triglycerides, cholesterol, cholesterol esters, and phospholipids and enter the lymphatics, not the portal vein. Defects in the postabsorptive phase of lipid digestion/absorption can also result in steatorrhea, but these disorders are uncommon. Abetalipoproteinemia, or acanthocytosis, is a rare disorder of impaired synthesis of β-lipopro tein associated with abnormal erythrocytes (acanthocytes), neurologic problems, and steatorrhea (Chap. 400). Lipolysis, micelle formation, and lipid uptake are all normal in patients with abetalipoproteinemia, but the re-esterified triglyceride cannot exit the epithelial cell because of the failure to produce chylomicrons. Small-intestinal biopsy samples obtained from these rare patients in the postprandial state reveal lip id-laden small-intestinal epithelial cells that become perfectly normal in appearance after a 72- to 96-h fast. Similarly, abnormalities of intestinal lymphatics (e.g., intes tinal lymphangiectasia) may also be associated with steatorrhea as well as protein loss (see below). Steatorrhea can result from defects at any of the several steps in lipid digestion/absorption. The mechanism of lipid digestion/absorption outlined above is limited to dietary lipid, which is almost exclusively in the form of LCTs (Table 318-3). Medium-chain triglycerides (MCTs), com posed of fatty acids with carbon chain lengths of 8–12, are present in large amounts in coconut oil and are used as a nutritional supplement. MCTs can be digested and absorbed by a pathway dif ferent from that involved in LCT digestion and absorption; at one time, MCTs held promise as an important treatment for steatorrhea of almost all etiologies. Unfortunately, they have been less therapeutically effective than expected because, for reasons that are not completely understood, their use often is not associated with an increase in body weight. CHAPTER 318 Disorders of Absorption Lymphatics Lipolysis Fatty acids Triglycerides Micellar Solubilization with Bile Acid Absorption (1) Esterification Fatty acids β-Monoglyceride Triglycerides β-Monoglyceride Cholesterol Phospholipid β–Lipoprotein (2) Chylomicron formation Delivery To tissues for utilization of fat FIGURE 318-2 Schematic representation of lipid digestion and absorption. Dietary lipid is in the form of long-chain triglycerides. The overall process can be divided into (1) a digestive phase that includes both lipolysis and micelle formation requiring pancreatic lipase and conjugated bile acids, respectively, in the duodenum; (2) an absorptive phase for mucosal uptake and re-esteri cation; and (3) a postabsorptive phase that includes chylomicron formation and exit from the intestinal epithelial cell via lymphatics. (Courtesy of John M. Dietschy, MD; with permission.) 2248 TABLE 318-5 Primary Lactase Deficiency in Adult Ethnic Groups ETHNIC GROUP Northern European Mediterranean African black African American American white Native American Mexican American Asian PREVALENCE OF LACTASE DEFICIENCY, % 5–15 60–85 85–100 45–80 10–25 50–95 40–75 90–100 Source: From FJ Simoons: Am J Dig Dis 23:963, 1978. PART 10 Disorders of the Gastrointestinal System primary lactase deficiency in several ethnic groups. Lactase persistence in adults is an abnormality due to a defect in the regulation of its matu ration. In contrast, secondary lactase deficiency occurs in association with small-intestinal mucosal disease, with abnormalities in both structure and function of other brush border enzymes and transport processes. Secondary lactase deficiency is often seen in celiac disease. As lactose digestion is rate-limiting compared to glucose/galactose absorption, lactase deficiency is associated with significant lactose malabsorption. Some individuals with lactose malabsorption develop symptoms such as diarrhea, abdominal pain, cramps, and/or flatus. Most individuals with primary lactase deficiency do not have symp toms. Since lactose intolerance may be associated with symptoms sug gestive of irritable bowel syndrome, persistence of such symptoms in an individual who exhibits lactose intolerance while on a strict lactose free diet suggests that the person’s symptoms were related to irritable bowel syndrome. The development of symptoms of lactose intolerance is related to several factors: In contrast to LCTs, MCTs do not require pancreatic lipolysis as they can be absorbed intact by the intestinal epithelial cell. Further, micelle formation is not necessary for the absorption of MCTs (or MCFAs, if hydrolyzed by pancreatic lipase). MCTs are absorbed more efficiently than LCTs for the following reasons: (1) The rate of absorption is greater for MCTs than for LCFAs; (2) after absorption, MCFAs are not re-esterified; (3) after absorption, MCTs are hydrolyzed to MCFAs; (4) MCTs do not require chylomicron formation to exit intestinal epithe lial cells; and (5) the route of MCT exit is via the portal vein and not via lymphatics. Thus, the absorption of MCTs is greater than that of LCTs in pancreatic insufficiency, conditions with reduced intraduodenal bile-acid concentrations, small-intestinal mucosal disease, abetalipo proteinemia, and intestinal lymphangiectasia. SCFAs are not dietary lipids but are synthesized by colonic bacterial enzymes from nonabsorbed carbohydrate and are the anions present at the highest concentration in stool (80–130 mM). The SCFAs in stool are primarily acetate, propionate, and butyrate, whose carbon chain lengths are 2, 3, and 4, respectively. Butyrate is the primary nutrient for colonic epithelial cells, and its deficiency can be associated with one or more colitides. SCFAs conserve calories and carbohydrate: carbohydrates that are not completely absorbed in the small intestine will not be absorbed in the large intestine because of the absence of both disaccharidases and SGLT1, the transport protein that mediates monosaccharide absorption. In contrast, SCFAs are rapidly absorbed and stimulate colonic NaCl and fluid absorption. Most antibiotic- associated diarrhea not caused by Clostridium difficile is due to antibiotic suppression of the colonic microbiota, with a resulting decrease in SCFA production. As C. difficile accounts for only ~15–20% of all anti biotic-associated diarrhea, a relative decrease in colonic production of SCFA is likely the cause of most antibiotic-associated diarrhea. The clinical manifestations of steatorrhea are a consequence both of the underlying disorder responsible for its development and of steat orrhea per se. Depending on the degree of steatorrhea and the level of dietary intake, significant fat malabsorption may lead to weight loss. Steatorrhea per se can be responsible for diarrhea; if the primary cause of the steatorrhea has not been identified, a low-fat diet can often ame liorate the diarrhea by decreasing fecal fat excretion. Steatorrhea is com monly associated with fat-soluble vitamin deficiency, which requires replacement with water-soluble preparations of these vitamins. Disorders of absorption may also be associated with malabsorption of other dietary nutrients—most often carbohydrates—with or without a decrease in dietary lipid digestion and absorption. Therefore, knowl edge of the mechanisms of digestion and absorption of carbohydrates, proteins, and other minerals and vitamins is useful in the evaluation of patients with altered intestinal nutrient absorption. ■CARBOHYDRATES Carbohydrates in the diet are present in the form of starch, disaccha rides (sucrose and lactose), and glucose. Carbohydrates are absorbed only in the small intestine and only in the form of monosaccharides. Therefore, before their absorption, starch and disaccharides must first be digested by pancreatic amylase and intestinal brush border disac charidases to monosaccharides. Monosaccharide absorption occurs by a Na-dependent process mediated by the brush border transport protein SGLT1. Lactose malabsorption is the only clinically important disorder of carbohydrate absorption. Lactose, the disaccharide present in milk, requires digestion by brush border lactase to its two constituent monosaccharides, glucose and galactose. Lactase is present in almost all species in the postnatal period but then disappears throughout the animal kingdom, except in humans. Lactase activity persists in many individuals throughout life. Two different types of lactase deficiency exist—primary and secondary. In primary lactase deficiency, a genetically determined decrease or absence of lactase is noted, while all other aspects of both intestinal absorption and brush border enzymes are normal. In a number of nonwhite groups, primary lactase deficiency is common in adulthood. In fact, Northern European and North Amer ican whites are the only groups to maintain small-intestinal lactase activity throughout adult life. Table 318-5 presents the incidence of 1. Amount of lactose in the diet. 2. Rate of gastric emptying. Symptoms are more likely when gastric emp tying is rapid than when it is slower. Therefore, skim milk is more likely to be associated with symptoms of lactose intolerance than whole milk, as the rate of gastric emptying after skim milk intake is more rapid. Similarly, diarrhea following subtotal gastrectomy is often a result of lactose intolerance, as gastric emptying is acceler ated in patients with a gastrojejunostomy. 3. Small-intestinal transit time. Although the small and large intestines both contribute to the development of symptoms, many symptoms of lactase deficiency are related to the interaction of colonic bacteria and nonabsorbed lactose. More rapid small-intestinal transit makes symptoms more likely. 4. Colonic compensation by production of SCFAs from nonabsorbed lactose. Reduced levels of colonic microflora, which can follow antibiotic use, are associated with increased symptoms after lactose ingestion, especially in a lactase-deficient individual. Glucose-galactose or monosaccharide malabsorption may also be associated with diarrhea and is due to a congenital absence of SGLT1. Diarrhea develops when individuals with this disorder ingest car bohydrates that contain actively transported monosaccharides (e.g., glucose, galactose) but not when they ingest monosaccharides that are not actively transported (e.g., fructose). Fructose is absorbed by the brush border transport protein GLUT 5, a facilitated diffusion process that is not Na-dependent and is distinct from SGLT1. In contrast, some individuals develop diarrhea as a result of the consumption of large quantities of sorbitol, a sugar used in diabetic candy; sorbitol is only minimally absorbed because of the absence of an intestinal absorptive transport mechanism for this sugar. ■PROTEINS Protein is present in food almost exclusively as polypeptides and requires extensive hydrolysis to di- and tripeptides and amino acids before absorption. Proteolysis occurs in both the stomach and the small intestine; it is mediated by pepsin, which is secreted as pepsinogen 2249 by gastric chief cells, and by trypsinogen and other peptidases from pancreatic acinar cells. The proenzymes pepsinogen and trypsinogen must be activated to pepsin (by pepsin at a pH <5) and trypsin (by the intestinal brush border enzyme enterokinase and subsequently by trypsin), respectively. Proteins are absorbed by separate transport sys tems for di- and tripeptides and for different types of amino acids—for example neutral and dibasic. Alterations in either protein or amino acid digestion and absorption are rarely observed clinically, even in the presence of extensive small-intestinal mucosal inflammation. However, three rare genetic disorders involve protein digestion/absorption: (1) Enterokinase deficiency is due to an absence of the brush border enzyme that converts the proenzyme trypsinogen to trypsin and is associated with diarrhea, growth retardation, and hypoproteinemia; (2) Hartnup’s syndrome, a defect in neutral amino acid transport, is characterized by a pellagra-like rash and neuropsychiatric symptoms; and (3) cystinuria, a defect in dibasic amino acid transport, is associated with renal calculi and chronic pancreatitis
POSTEST
Alur Sesi: 01 Pretest → 02 MATERI (AKTIF) → 03 POSTTEST
Broty: "Materi selesai dibaca. Lanjutkan ke posttest untuk mengevaluasi pemahamanmu pada sesi ini."
- Langkah Selanjutnya: Lanjut ke Posttest Sesi 1 →
- Navigasi Blok: Daftar Sesi Gastrointestinal · Beranda